Covid-19 Vaccine Status Oxford-AstraZeneca Johnson & Johnson

189 Aufrufe

  • Danke für die Bewertung! Teile es mit Deinen Freunden!

    Danke für Deine Bewertung!

admin
Published
Oxford-AstraZeneca vaccine status
The AZD1222 vaccine, being jointly developed by British pharma giant AstraZeneca and Oxford University, is presently undergoing phase II trials with 10,000 volunteers. The late-stage trials of the vaccine will be conducted in Brazil.

Testing of the experimental Covid-19 vaccine in healthy volunteers had begun in Britain in April with over 1,000 people aged 18 to 55.

Meanwhile, AstraZeneca has struck a deal with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses. The alliance, forged by Germany, France, Italy and the Netherlands to speed up production of a vaccine, will take delivery of the vaccine by the end of 2020.

Earlier this month, AstraZeneca stated it had started to mass-produce its experimental vaccine and planned to roll out up to two billion doses in September.

The Cambridge-based firm has signed deals to produce 400 million doses for the US and 100 million for the UK if it is successful in human trials.

Johnson & Johnson vaccine status
Initially planned for September, American firm Johnson & Johnson said it had fast-tracked the start of human clinical trials for its recombinant Ad26.COV2-S vaccine by two months to the second half of July. The decision may allow J&J to take part in the massive clinical trials program — Operation Warp Speed — planned by the US government.

In March, J&J signed deals with the US government to create enough manufacturing capacity to produce more than 1 billion dos
Kategorien
Corona Virus aktuelle Videos
Kommentare deaktiviert.

Als nächstes

Яндекс.Метрика Top.Mail.Ru